SIGA vs TOI

SIGA presents a stark contrast between a pristine balance sheet and a collapsing operational core, evidenced by a Piotroski F-Score of 4/9 (Stable). While the company maintains zero debt and an exceptional current ratio of 11.83, the YoY revenue decline of -95.30% and an operating margin of -250.38% indicate a severe crisis in business continuity. The current price of $4.76 trades at a premium to both the Graham Number ($4.47) and the Intrinsic Value ($2.24), suggesting the stock is overvalued relative to its fundamentals. Technical trends are fully bearish, and the earnings track record shows a consistent failure to meet analyst expectations.

The Oncology Institute (TOI) exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price/Book ratio of -22.14, indicating negative shareholders' equity. While the company shows impressive top-line revenue growth of 41.60% YoY, it remains unprofitable with negative operating and profit margins. There is a stark divergence between the 'Strong Buy' analyst consensus and the actual financial health and bearish insider selling patterns. The lack of a Graham Number or Altman Z-Score further underscores the company's distressed financial state.